Treatment Outcome of Brain Metastasis after the Cranial Radiotherapy Followed by Fractionated StereotacticRadiotherapy and Its Prognostic Factors
Treatment Outcome of Brain Metastasis after the Cranial Radiotherapy Followed by Fractionated Stereotactic Radiotherapy and Its Prognostic Factors
1
조회
0
다운로드
0
인용
0
참고문헌
초록
Purpose: To evaluate the effectiveness of whole brainradiotherapy followed by stereotactic radiotherapy fornewly diagnosed brain metastasis. Materials and Methods: Thirty-three metastatic braintumors received radiotherapy to the whole brain andstereotactic radiotherapy in 25 patients. Lung carcinomaswere the most common (17/25) primary tumor. Theradiation dose was 30 to 40 Gy for the whole brain, witha 12 to 40 Gy boost to the metastatic foci. Survival andlocal control rates were determined, and the prognosticfactors for survival were evaluated. Results: The overall median survival was 15 monthsand the actuarial survivals at 1- and 2-year were 67% and31%, respectively. The local tumor control rate was 79%,with a median follow-up period of 9 months (2က36months). The prognostic factors associated with survivalwere age, tumor size and the existence of active extracranialmetastasis, with the performance status showingmarginal significance. No acute or chronic complicationswere observed in the patients. Conclusion: From our data, cranial radiotherapy followedby stereotactic radiotherapy was useful in the localcontrol of metastatic tumors, and in the survival ofpatients with tumor factors, such as small size or theabsence of extracranial tumor activity, and host factors,such as young age or good performance status. (CancerRes Treat. 2002;34:284-288)
Abstract
Purpose: To evaluate the effectiveness of whole brainradiotherapy followed by stereotactic radiotherapy fornewly diagnosed brain metastasis. Materials and Methods: Thirty-three metastatic braintumors received radiotherapy to the whole brain andstereotactic radiotherapy in 25 patients. Lung carcinomaswere the most common (17/25) primary tumor. Theradiation dose was 30 to 40 Gy for the whole brain, witha 12 to 40 Gy boost to the metastatic foci. Survival andlocal control rates were determined, and the prognosticfactors for survival were evaluated. Results: The overall median survival was 15 monthsand the actuarial survivals at 1- and 2-year were 67% and31%, respectively. The local tumor control rate was 79%,with a median follow-up period of 9 months (2က36months). The prognostic factors associated with survivalwere age, tumor size and the existence of active extracranialmetastasis, with the performance status showingmarginal significance. No acute or chronic complicationswere observed in the patients. Conclusion: From our data, cranial radiotherapy followedby stereotactic radiotherapy was useful in the localcontrol of metastatic tumors, and in the survival ofpatients with tumor factors, such as small size or theabsence of extracranial tumor activity, and host factors,such as young age or good performance status. (CancerRes Treat. 2002;34:284-288)